Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...

Kenvue stock reversed lower Monday after the company — known for brands like Tylenol — announced a new CEO and strategic ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

Alongside the leadership change, Kenvue revealed that its Board had previously initiated a comprehensive review of strategic alternatives and established a Strategic Review Committee. The review will ...

Kenvue (NYSE:KVUE) recently experienced a 2% price increase over the past week, a move that coincides with notable executive changes. The replacement of the CEO with Kirk L. Perry as interim CEO, ...

Emerson Electric has restructured its business to focus on long-term growth opportunities. Kenvue is a good choice for ...